Target Name: LARP4B
NCBI ID: G23185
Review Report on LARP4B Target / Biomarker Content of Review Report on LARP4B Target / Biomarker
LARP4B
Other Name(s): La ribonucleoprotein domain family, member 5 | la-related protein 5 | LAR4B_HUMAN | RP11-164C1.3 | La-related protein 5 | La-related protein 4B (isoform 1) | La ribonucleoprotein domain family member 4B | La ribonucleoprotein 4B | DKFZp686M23113 | La ribonucleoprotein domain family member 5 | KIAA0217 | LARP5 | La-related protein 4B | LARP4B variant 1 | La ribonucleoprotein 4B, transcript variant 1

Overview of LARP4B: A Protein Involved in Gene Expression and DNA Damage Repair

The La ribonucleoprotein domain family (LARP4B) is a protein that plays a crucial role in various cellular processes. It is a member of the nucleoprotein subfamily and is found in different organisms, including bacteria, archaea, and eukaryotes. LARP4B is made up of 21 amino acid residues and has a calculated pI of 6.9.

One of the key functions of LARP4B is its role in the regulation of gene expression. LARP4B is a transcription factor that can bind to specific DNA sequences and regulate the expression of genes in the cell. This function is critical for the development, growth, and survival of the cell.

Another important function of LARP4B is its role in DNA damage repair. LARP4B is a component of the DNA damage repair machinery and can help to repair damaged DNA in the cell. This is important for the maintenance of genetic stability and for the prevention of genetic mutations that can lead to diseases such as cancer.

In addition to its functions in gene expression and DNA damage repair, LARP4B is also a potential drug target. Many studies have suggested that LARP4B may be a useful target for small molecule inhibitors because of its unique structure and its ability to interact with small molecules in a specific way.

One of the reasons for the potential of LARP4B as a drug target is its unique structure. LARP4B is a small protein with only 21 amino acid residues. This small size makes it relatively easy to target and implies that it has a limited number of interactions with small molecules. Additionally, LARP4B has a specific localization in the cell, which makes it easier to selectively target it.

Another reason for the potential of LARP4B as a drug target is its ability to interact with small molecules. LARP4B has been shown to interact with a variety of small molecules, including inhibitors of DNA damage repair, metabolism, and inflammation. This suggests that LARP4B may be a useful target for small molecule inhibitors because it can be modulated by these molecules.

In addition to its potential as a drug target, LARP4B is also a potential biomarker. The La ribonucleoprotein domain is a common protein found in many organisms, including bacteria, archaea, and eukaryotes. This suggests that LARP4B may be a useful biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, LARP4B is a protein that plays a crucial role in various cellular processes, including gene expression and DNA damage repair. Its unique structure and ability to interact with small molecules make it a potential drug target. In addition, LARP4B is also a potential biomarker for various diseases. Further research is needed to fully understand the functions of LARP4B and its potential as a drug and biomarker.

Protein Name: La Ribonucleoprotein 4B

Functions: Stimulates mRNA translation

The "LARP4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LARP4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LARP4P | LARP6 | LARP7 | LARS1 | LARS2 | LAS1L | LASP1 | LAT | LAT2 | LATS1 | LATS2 | LAX1 | LAYN | LBH | LBHD1 | LBP | LBR | LBX1 | LBX1-AS1 | LBX2 | LBX2-AS1 | LCA5 | LCA5L | LCAL1 | LCAT | LCDR | LCE1A | LCE1B | LCE1C | LCE1D | LCE1E | LCE1F | LCE2A | LCE2B | LCE2C | LCE2D | LCE3A | LCE3B | LCE3C | LCE3D | LCE3E | LCE4A | LCE5A | LCE6A | LCIIAR | LCK | LCLAT1 | LCMT1 | LCMT2 | LCN1 | LCN10 | LCN12 | LCN15 | LCN1P1 | LCN1P2 | LCN2 | LCN6 | LCN8 | LCN9 | LCNL1 | LCOR | LCORL | LCP1 | LCP2 | LCT | LCT-AS1 | LCTL | LDAF1 | LDAH | LDB1 | LDB2 | LDB3 | LDC1P | LDHA | LDHAL6A | LDHAL6B | LDHAL6CP | LDHAP5 | LDHB | LDHBP1 | LDHC | LDHD | LDLR | LDLRAD1 | LDLRAD2 | LDLRAD3 | LDLRAD4 | LDLRAP1 | LDOC1 | LEAP2 | LECT2 | LEF1 | LEF1-AS1 | LEFTY1 | LEFTY2 | LEKR1 | LELP1 | LEMD1 | LEMD1-AS1 | LEMD2